The Experts below are selected from a list of 12 Experts worldwide ranked by ideXlab platform
Alf Hamann - One of the best experts on this subject based on the ideXlab platform.
-
Transfer of IFNγ-depleted CD4+ T cells together with CD8+ T cells leads to rejection of murine Kidney Sarcoma in mice
International journal of cancer, 2000Co-Authors: Katja Klugewitz, Alexander Scheffold, Andreas Radbruch, Alf HamannAbstract:In the murine Kidney Sarcoma, vaccination with the tumor-specific large T antigen induces protective immunity against the tumor. Immunity is dependent both on CD8(+) cytotoxic T cells and on CD4(+) T-helper cells. We analyzed whether the cytokine phenotype of induced CD4(+) T-effector cells might determine whether or not the tumor is successfully rejected. By intracytoplasmic staining of CD4(+) cells, IFNgamma-producing (Th1), IL-4-producing (Th2), and IL-10-expressing cells could be identified in vaccinated and non-vaccinated animals responding to tumor growth. Vaccinated mice rejecting the tumor showed an increase in the percentage of IL-4-producing (Th2) cells. In contrast, in non-vaccinated mice succumbing to the tumor, the immunosuppressive IL-10-producing cells became more abundant and the frequency of IFNgamma-expressing cells dropped at later time points. Yet, dominance by either a Th1 or a Th2 response could not be observed. To further clarify the relevance of these subsets, Th1 cells were enriched by cell sorting according to IFNgamma surface expression. Enriched Th1 and depleted cells, mainly consisting of the Th2 phenotype, were transferred together with CD8(+) T cells. Surprisingly, immunity could be transferred either with Th1 or Th2 cells, but Th2 cells were slightly more efficient. This suggests that, at least in the effector phase, a Th1 phenotype is not crucial for the rejection. Our findings support the view that the Th1/Th2 dichotomy is not central in T-cell-mediated tumor rejection.
Katja Klugewitz - One of the best experts on this subject based on the ideXlab platform.
-
Transfer of IFNγ-depleted CD4+ T cells together with CD8+ T cells leads to rejection of murine Kidney Sarcoma in mice
International journal of cancer, 2000Co-Authors: Katja Klugewitz, Alexander Scheffold, Andreas Radbruch, Alf HamannAbstract:In the murine Kidney Sarcoma, vaccination with the tumor-specific large T antigen induces protective immunity against the tumor. Immunity is dependent both on CD8(+) cytotoxic T cells and on CD4(+) T-helper cells. We analyzed whether the cytokine phenotype of induced CD4(+) T-effector cells might determine whether or not the tumor is successfully rejected. By intracytoplasmic staining of CD4(+) cells, IFNgamma-producing (Th1), IL-4-producing (Th2), and IL-10-expressing cells could be identified in vaccinated and non-vaccinated animals responding to tumor growth. Vaccinated mice rejecting the tumor showed an increase in the percentage of IL-4-producing (Th2) cells. In contrast, in non-vaccinated mice succumbing to the tumor, the immunosuppressive IL-10-producing cells became more abundant and the frequency of IFNgamma-expressing cells dropped at later time points. Yet, dominance by either a Th1 or a Th2 response could not be observed. To further clarify the relevance of these subsets, Th1 cells were enriched by cell sorting according to IFNgamma surface expression. Enriched Th1 and depleted cells, mainly consisting of the Th2 phenotype, were transferred together with CD8(+) T cells. Surprisingly, immunity could be transferred either with Th1 or Th2 cells, but Th2 cells were slightly more efficient. This suggests that, at least in the effector phase, a Th1 phenotype is not crucial for the rejection. Our findings support the view that the Th1/Th2 dichotomy is not central in T-cell-mediated tumor rejection.
Alexander Scheffold - One of the best experts on this subject based on the ideXlab platform.
-
Transfer of IFNγ-depleted CD4+ T cells together with CD8+ T cells leads to rejection of murine Kidney Sarcoma in mice
International journal of cancer, 2000Co-Authors: Katja Klugewitz, Alexander Scheffold, Andreas Radbruch, Alf HamannAbstract:In the murine Kidney Sarcoma, vaccination with the tumor-specific large T antigen induces protective immunity against the tumor. Immunity is dependent both on CD8(+) cytotoxic T cells and on CD4(+) T-helper cells. We analyzed whether the cytokine phenotype of induced CD4(+) T-effector cells might determine whether or not the tumor is successfully rejected. By intracytoplasmic staining of CD4(+) cells, IFNgamma-producing (Th1), IL-4-producing (Th2), and IL-10-expressing cells could be identified in vaccinated and non-vaccinated animals responding to tumor growth. Vaccinated mice rejecting the tumor showed an increase in the percentage of IL-4-producing (Th2) cells. In contrast, in non-vaccinated mice succumbing to the tumor, the immunosuppressive IL-10-producing cells became more abundant and the frequency of IFNgamma-expressing cells dropped at later time points. Yet, dominance by either a Th1 or a Th2 response could not be observed. To further clarify the relevance of these subsets, Th1 cells were enriched by cell sorting according to IFNgamma surface expression. Enriched Th1 and depleted cells, mainly consisting of the Th2 phenotype, were transferred together with CD8(+) T cells. Surprisingly, immunity could be transferred either with Th1 or Th2 cells, but Th2 cells were slightly more efficient. This suggests that, at least in the effector phase, a Th1 phenotype is not crucial for the rejection. Our findings support the view that the Th1/Th2 dichotomy is not central in T-cell-mediated tumor rejection.
Andreas Radbruch - One of the best experts on this subject based on the ideXlab platform.
-
Transfer of IFNγ-depleted CD4+ T cells together with CD8+ T cells leads to rejection of murine Kidney Sarcoma in mice
International journal of cancer, 2000Co-Authors: Katja Klugewitz, Alexander Scheffold, Andreas Radbruch, Alf HamannAbstract:In the murine Kidney Sarcoma, vaccination with the tumor-specific large T antigen induces protective immunity against the tumor. Immunity is dependent both on CD8(+) cytotoxic T cells and on CD4(+) T-helper cells. We analyzed whether the cytokine phenotype of induced CD4(+) T-effector cells might determine whether or not the tumor is successfully rejected. By intracytoplasmic staining of CD4(+) cells, IFNgamma-producing (Th1), IL-4-producing (Th2), and IL-10-expressing cells could be identified in vaccinated and non-vaccinated animals responding to tumor growth. Vaccinated mice rejecting the tumor showed an increase in the percentage of IL-4-producing (Th2) cells. In contrast, in non-vaccinated mice succumbing to the tumor, the immunosuppressive IL-10-producing cells became more abundant and the frequency of IFNgamma-expressing cells dropped at later time points. Yet, dominance by either a Th1 or a Th2 response could not be observed. To further clarify the relevance of these subsets, Th1 cells were enriched by cell sorting according to IFNgamma surface expression. Enriched Th1 and depleted cells, mainly consisting of the Th2 phenotype, were transferred together with CD8(+) T cells. Surprisingly, immunity could be transferred either with Th1 or Th2 cells, but Th2 cells were slightly more efficient. This suggests that, at least in the effector phase, a Th1 phenotype is not crucial for the rejection. Our findings support the view that the Th1/Th2 dichotomy is not central in T-cell-mediated tumor rejection.
Katsuo Aizawa - One of the best experts on this subject based on the ideXlab platform.
-
A Comparison between Argon‐dye and Excimer‐dye Laser for Photodynamic Effect in Transplanted Mouse Tumor
Japanese journal of cancer research : Gann, 1992Co-Authors: Tetsuya Okunaka, Harubumi Kato, Chimori Konaka, Harumasa Sakai, Hirofumi Kawabe, Katsuo AizawaAbstract:Photodynamic therapy (PDT) utilizing a hematoporphyrin derivative (HpD) as a sensitizer has become a viable option for the local treatment of neoplastic disease. The argon-dye laser system is commonly used as a light source in this treatment modality. The excimer-dye laser, on the other hand, delivers high-energy red light in a pulsatile fashion. In this investigation, we treated BALB/c mice bearing mouse Kidney Sarcoma cell tumors with PDT using HpD at the dose of 5 mg/kg body weight as a photosensitizer and either a standard argon-dye laser or the pulsatile excimer-dye laser as the light source. At equal light energy doses (50 J/cm2), necrotic changes at depths averaging 4 mm from the tumor surface were obtained with the argon-dye laser (200 mW power output) while tumor necrosis at depths exceeding 15 mm from the tumor surface was obtained using the excimer-dye laser (6 mJ/pulse, 5 Hz). To determine the best conditions for photoirradiation with the excimer-dye laser, tumor-bearing mice were treated with different total light doses (10, 30 and 50 J/cm2), dose rates (1, 3 and 6 mJ/cm2), and frequencies (5, 15 and 50 Hz) of light exposure. Our results indicate that the optimal effects obtained with the excimer-dye laser are related to the total light dose used and the dose rate, but not to the frequency of light exposure.
